CRDF (Cardiff Oncology) Other Current Assets: $1.10 Mil (As of Mar. 2026)


CRDF Cardiff Oncology Inc CRDF
48 GF Score
Price $1.27
GF Value $1.43
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Cardiff Oncology Other Current Assets?

Cardiff Oncology CRDF -7.58% 48 Other Current Assets is $1.10 Mil as of Mar. 2026. GuruFocus rates CRDF with a GF Score™ of 48/100 and a GF Value™ of $1.43 (Modestly Undervalued). The stock has 4 warning signs investors should review.

Cardiff Oncology's other current assets for the quarter that ended in Mar. 2026 was $1.10 Mil.

Cardiff Oncology's quarterly other current assets increased from Sep. 2025 ($0.96 Mil) to Dec. 2025 ($1.64 Mil) but then declined from Dec. 2025 ($1.64 Mil) to Mar. 2026 ($1.10Mil).

Cardiff Oncology's annual other current assets increased from Dec. 2023 ($2.30 Mil) to Dec. 2024 ($2.54 Mil) declined from Dec. 2024 ($2.54 Mil) to Dec. 2025 ($1.64 Mil).


Cardiff Oncology Other Current Assets Related Terms


Cardiff Oncology Other Current Assets Historical Data

* Premium members only.

The historical data trend for Cardiff Oncology's Other Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cardiff Oncology Other Current Assets Chart

Cardiff Oncology Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.77 5.25 2.30 2.54 1.64

Cardiff Oncology Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.42 2.21 0.96 1.64 1.10
CRDF
48GF Score
Cardiff Oncology Inc CRDF
Other Current Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cardiff Oncology Other Current Assets Calculation

Technically, the other current assets line may include any asset that will be used up within the next 12 months. However, other current assets never include assets that are listed elsewhere in the current assets section of the balance sheet. For this reason, other current assets are almost never:


Cash
Trade Receivables
Inventory

The assets grouped under other current assets are most commonly:


Prepaid Expenses
Tax Assets
Non-Trade Receivables
Other (too numerous to list)

Some companies can and do choose to report each of these items separately.

Other current assets may be made up largely of Prepaid Expenses - unless these are listed on a separate line of the balance sheet.

Prepaid expenses are exactly what they sound like. If a company pays a $30 million insurance premium on the last day of June that will provide coverage for the entire month of July, the company will record a $30 million prepaid expense to account for the insurance expense it will show in July that it already paid for in June.

Tax assets can be quite complex. It is not common for companies to have both tax assets and tax liabilities. It is important that investors take note of both items when considering future taxes.

Non-Trade receivables are rarely a large item. They include money owed to the company by non-customers. Non-trade receivables can be caused by related party transactions, the sale of a business unit, etc. The notes to the company's financial statements will often provide much more detail on this item if it is truly important.

There are a variety of other current assets like non-trade receivables which are simply too numerous to list. If a company is following correct reporting procedures, it should not lump items that are different from one another and yet individually important to the company together under the line Other Current Assets.

At most companies, other current assets are a small and unimportant part of the total balance sheet.

Frequently Asked Questions Learn more about Other Current Assets →
What does a Other Current Assets of $1.10 Mil mean?
Cardiff Oncology (CRDF) has a Other Current Assets of $1.10 Mil as of Mar. 2026. Other current assets as record on a company's balance sheet not categorized as standard assets. View historical data on Cardiff Oncology.
Is Cardiff Oncology's Other Current Assets too high?
Cardiff Oncology's current Other Current Assets is $1.10 Mil. Overall, Cardiff Oncology has a GF Score™ of 48/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cardiff Oncology's Other Current Assets compare to MAIA and TELO?
Cardiff Oncology's Other Current Assets of $1.10 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Assets for a Biotechnology company?
A good Other Current Assets depends on the Biotechnology industry context. However, Other Current Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Assets mean?
A high Other Current Assets can signal that a stock is expensive relative to its fundamentals. Other current assets as record on a company's balance sheet not categorized as standard assets. View historical data on Cardiff Oncology. Cardiff Oncology's current Other Current Assets is $1.10 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cardiff Oncology stock overvalued right now?
Based on GuruFocus' analysis, Cardiff Oncology (CRDF) is currently considered Modestly Undervalued. The stock's GF Value™ is $1.43, compared to a current price of $1.27 — trading 11.5% below its estimated fair value. The current Other Current Assets is $1.10 Mil. Cardiff Oncology's overall GF Score™ is 48/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Assets calculated?
Other Current Assets is calculated from a company's financial statements. For Cardiff Oncology (CRDF), the current Other Current Assets is $1.10 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cardiff Oncology (CRDF) Overvalued in 2026?

Based on GuruFocus' analysis, Cardiff Oncology stock appears to be undervalued. The current stock price of $1.27 is trading 11.5% below its estimated GF Value™ of $1.43. GuruFocus considers Cardiff Oncology to be Modestly Undervalued.

Key valuation signals for CRDF:

  • Other Current Assets: $1.10 Mil
  • GF Value™: $1.43 vs. price of $1.27 (11.5% below fair value)
  • GF Score™: 48/100 with 4 warning signs

No single metric tells the full story. See the CRDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Cardiff Oncology Business Description

Other Exchanges XE7C:Germany
Address 11055 Flintkote Avenue, San Diego, CA, USA, 92121
Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.
48GF Score

Get the complete analysis for CRDF

Other Current Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.27
Price
$1.43
GF Value